Jefferies Reiterates Buy on Amgen (AMGN) Following FDA Approval of Humira Biosimilar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amgen (AMGN): Launch of ABP-501 Could Be Delayed Until 2023 - BMO
July 12, 2016 7:54 PM EDTBMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on Amgen (NASDAQ: AMGN) and price target of $186. After the FDA Advisory Committee voted 26-0 in favor of approval for ABP-501, Amgens biosimilar Humira. However, the market reaction may not be as... More
Guggenheim Highlights Latest Specialty Pharma Short Interest Data (HZNP) (VRX) (PRGO) (SHPG) (AGN)
July 12, 2016 4:59 PM EDTGuggenheim analyst Louise Chen broke down the latest short interest data (6/30/2016) for the Specialty Pharmaceutical sector and other key Pharma/Biotech players.
The analyst notes stocks with the largest increase in short interest is AcelRx Pharmaceuticals (NASDAQ: ACRX) at +30.9%, followed by Horizon... More
AbbVie (ABBV) on Watch After Amgen (AMGN) Wins FDA Backing for Humira Biosimilar
July 12, 2016 4:26 PM EDTAbbVie (NYSE: ABBV) on Watch After Amgen (Nasdaq: AMGN) Wins FDA Backing for Humira Biosimilar
... MoreAmgen (AMGN) wins FDA panel backing for biosimilar Humira in U.S. - Bloomberg
July 12, 2016 4:23 PM EDTAmgen (NASDAQ: AMGN) wins FDA panel backing for biosimilar Humira in U.S., according to Bloomberg. The panel voted 26 - 0 on the measure.
... MoreAmgen (AMGN) Announces Meeting with U.S. FDA to Discuss ABP 501 BLA
July 12, 2016 7:32 AM EDTAmgen (Nasdaq: AMGN) announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee. ABP 501 is a biosimilar candidate to Humira® (adalimumab), an anti-tumor necrosis factor-alpha (TNF-) monoclonal antibody, which is approved in many regions for the treatment... More
Amgen's (AMGN) Repatha Pushtronex System Receives FDA Approval
July 11, 2016 9:03 AM EDTAmgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg of Repatha in a single dose. Repatha is a human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9), which inhibits the body's natural system for eliminating "bad" cholesterol (low-density lipoprotein cholesterol or LDL-C) from the blood.1 Repatha is the first and only PCSK9 inhibitor to offer a... More
